^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HB0036

    i
    Other names: HB0036, HB 0036, HB-0036
    Associations

    News

    Trials
    Company:
    Zhejiang Huahai Pharma
    Drug class:
    PD-L1 inhibitor, TIGIT inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    Enhancing anti-tumor immunity through co-blocking PD-L1 and TIGIT by facilitating tumor-directed responses and additional VEGF inhibition. (PubMed, Front Immunol)
    Firstly, we demonstrated that the bispecific antibody (HB0036) for PD-L1 and TIGIT co-blockade induced a greater T-cell proliferative response in vitro compared to the combined administration of the parental antibodies...Lastly, considering the heterogeneity of tumors, we analyzed how the expression patterns of PD-L1 and CD155 influence T cell responses. We also examined the spatial distribution of PD-L1 and CD155, along with related immunological parameters from patient samples, to assess the potential of PD-L1 and TIGIT co-blockade in diverse tumor contexts.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • PVR (PVR Cell Adhesion Molecule) • CD226 (CD226 Molecule)
    |
    HB0036
    1year
    A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=80, Recruiting, Shanghai Huaota Biopharmaceutical Co., Ltd. | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK mutation
    |
    HB0036
    over3years
    A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=80, Recruiting, Shanghai Huaota Biopharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK mutation
    |
    HB0036
    over3years
    A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=80, Not yet recruiting, Shanghai Huaota Biopharmaceutical Co., Ltd.
    New P1/2 trial
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK mutation
    |
    HB0036